The protease and reverse transcriptase (RT) genes were studied in antiretroviral (ARV)-
experienced and drug-naive HIV-I-infected individuals in Libreville, Gabon. We have shown …

To describe prevalence of antiretroviral (ARV) drug-resistant HIV-1 strains among patients
with a history of earlier treatment with ARV drugs in Abidjan, Côte d'Ivoire, we determined …

Background With widespread use of antiretroviral (ARV) drugs in Africa, one of the major
potential challenges is the risk of emergence of ARV drug‐resistant HIV strains. Our …

Objective To determine the genetic diversity of HIV-1 reverse transcriptase (RT) and
protease sequences and the presence of mutations linked to antiretroviral (ARV) resistance …

To evaluate the presence of drug resistance mutations in antiretroviral-naive patients in
Dakar (Senegal), cross-sectional studies were conducted since the circulation of ARVs in …

The last ten years have witnessed a significant scale-up and access to antiretroviral therapy
in Africa, which has improved patient quality of life and survival. One major challenge …

Introduction As antiretroviral treatment (ART) continues to expand in resource‐limited
countries, the emergence of HIV drug resistance mutations (DRMs) is challenging in these …

The distribution of antiretroviral (ARV) therapy resistance mutations among HIV-1 strains
was evaluated in 39 postpartum women, one pregnant woman, and 12 HIV-positive babies …

BACKGROUND: Infections with drug-resistant HIV viruses in naïve subjects may cause
antiretroviral (ARV) treatment failure. The prevalence of ARV resistance mutations in HIV-1 …

This study examined the emergence and prevalence of drug-resistant mutations in reverse
transcriptase and protease coding regions in human immunodeficiency virus type 1 (HIV-1) …